GAMMA Investing LLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

GAMMA Investing LLC raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4,005.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,230 shares of the specialty pharmaceutical company’s stock after purchasing an additional 42,177 shares during the quarter. GAMMA Investing LLC owned about 0.08% of Supernus Pharmaceuticals worth $1,320,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Raiffeisen Bank International AG acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $25,000. Versant Capital Management Inc grew its stake in shares of Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,109 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $42,000. Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 870 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $52,000.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $32.03 on Monday. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of 29.93 and a beta of 0.71. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.55 and a 1 year high of $40.28. The firm’s 50 day moving average price is $32.02 and its two-hundred day moving average price is $34.32.

Analysts Set New Price Targets

SUPN has been the subject of a number of research reports. Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 16th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.